MultiCell Technologies, Inc.

Equities

MCET

US62544S2005

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:37:50 2024-04-29 am EDT			5-day change	1st Jan Change
0.00001 ^USD	+900.00%		0.00%	+900.00%

2015	MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt	CI
2014	MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application	CI

MultiCell Technologies, Inc. Adds Scott Lukeman to its Board of Directors

September 06, 2012 at 01:50 pm EDT

MultiCell Technologies, Inc. has added Scott Lukeman, Ph.D., to its board of directors. He has over 25 years of international experience across multiple life-science disciplines in management, strategic planning, business and technology valuation and development, marketing, licensing, fund-raising and competitive intelligence.

Latest news about MultiCell Technologies, Inc.

MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt	15-03-01	CI
MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application	14-12-10	CI
MultiCell Technologies Inc. Files U.S. and International Patent Applications for the Treatment of Liver Cancer	14-03-20	CI
MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt	14-02-28	CI
MultiCell Technologies, Inc. Files U.S. Provisional Patent Application for its New Class of RNA Therapeutics	14-01-15	CI
MultiCell Technologies, Inc. Files U.S. Patent Application for Targeted Delivery of MCT-485	13-11-13	CI
MultiCell Technologies, Inc. and Genisphere, LLC Evaluate Targeted Delivery of MCT-485	13-08-06	CI
Multicell Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2013	13-07-24	CI
MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt	13-02-28	CI
Grant G. Miller Joins Board of MultiCell Technologies, Inc	12-10-22	CI
MultiCell Technologies, Inc. Adds Scott Lukeman to its Board of Directors	12-09-06	CI
MultiCell Technologies, Inc. Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in Vitro Models	12-08-10	CI
MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt	12-02-28	CI

Chart MultiCell Technologies, Inc.

Duration

Period

More charts

Company Profile

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MULTICELL TECHNOLOGIES, INC.	+900.00%	50.01K
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+47.70%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research